Figure 2.

Sustained E6F6 administration eradicate HBV infection efficiently. (A) AAV-HBV mice (n = 8/group; HBsAg: 1 × 10³–2 × 10⁴ IU/mL) were administrated with E6F6 intravenously as indicated by blue arrows, the time of blood sampling was indicated by red arrows. Vehicle was injected intravenously as control. Schematic representation of the short-term E6F6 therapy procedure. (B) Time kinetic of HBsAg in male AAV-HBV mice during short-term E6F6 administration. (C) AAV-HBV mice (n = 4/group; HBsAg: 1 × 10³–2 × 10⁴ IU/mL) were administrated with E6F6 intravenously. Schematic representation of the long-term E6F6 therapy procedure. (D) Time kinetic of HBsAg in male AAV-HBV mice during long-term E6F6 administration. Results were representative of three independent experiments. Statistical analyses were performed between red line and black line. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.